



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis

Citation for published version:

Int CAPP Consortium, Burn, J, Bishop, DT, Chapman, PD, Elliott, F, Bertario, L, Dunlop, MG, Eccles, D, Ellis, A, Evans, DG, Fodde, R, Maher, ER, Moeslein, G, Vasen, HFA, Coaker, J, Phillips, RKS, Bulow, S & Mathers, JC 2011, 'A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis', *Cancer Prevention Research*, vol. 4, no. 5, pp. 655-665. <https://doi.org/10.1158/1940-6207.CAPR-11-0106>

Digital Object Identifier (DOI):

[10.1158/1940-6207.CAPR-11-0106](https://doi.org/10.1158/1940-6207.CAPR-11-0106)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Cancer Prevention Research

Publisher Rights Statement:

The publisher's final edited version of this article is available at Cancer Prev Res (Phila)

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Published in final edited form as:

Cancer Prev Res (Phila). 2011 May ; 4(5): 655–665. doi:10.1158/1940-6207.CAPR-11-0106.

A Randomized Placebo-controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis

John Burn¹, D. Timothy Bishop³, Pamela D. Chapman¹, Faye Elliott³, Lucio Bertario¹⁰, Malcolm G. Dunlop⁴, Diana Eccles⁵, Anthony Ellis⁶, D. Gareth Evans⁷, Ricardo Fodde¹¹, Eamonn R. Maher⁸, Gabriela Möslein¹³, Hans F. A. Vasen¹², Julie Coaker², Robin K. S. Phillips⁹, Steffen Bülow¹⁴, and John C. Mathers² on behalf of the International CAPP consortium¹⁵

¹Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne ²Human Nutrition Research Centre, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne ³Section of Epidemiology & Biostatistics, Leeds Institute of Molecular Medicine, Leeds University, Leeds ⁴MRC Human Genetics Unit, Western General Hospital, Edinburgh ⁵Clinical Genetics Unit, Princess Anne Hospital, Southampton ⁶Gastroenterology Unit, Royal Liverpool University Hospital, Liverpool ⁷Department of Medical Genetics, St Mary's Hospital, Manchester ⁸Department of Medical and Molecular Genetics, University of Birmingham, Birmingham ⁹Polyposis Registry, St Mark's Hospital, Harrow London—all in United Kingdom ¹⁰Istituto Nazionale per lo Studio e, la Cura dei Tumori, Milan, Italy ¹¹Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam ¹²Netherlands Foundation of the Detection of Hereditary Tumours and Department of Gastroenterology, Leiden University Medical Centre, Leiden, The Netherlands ¹³St. Josefs-Hospital, Bochum-Linden, Germany ¹⁴Dept of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen, Denmark

Abstract

Evidence supporting aspirin and resistant starch (RS) for colorectal cancer prevention comes from epidemiological and laboratory studies (aspirin and RS) and randomized controlled clinical trials (aspirin). Familial adenomatous polyposis (FAP) strikes young people and, untreated, confers virtually a 100% risk of colorectal cancer and early death. We conducted an international, multicenter, randomized, placebo-controlled trial of aspirin (600 mg/day) and/or RS (30 g/day) for from 1 to 12 years to prevent disease progression in FAP patients from 10 to 21 years of age. In a 2 × 2 factorial design, patients were randomly assigned to the following four study arms: aspirin plus RS placebo; RS plus aspirin placebo; aspirin plus RS; RS placebo plus aspirin placebo; they were followed with standard annual clinical examinations including endoscopy. The primary endpoint was polyp number in the rectum and sigmoid colon (at the end of intervention), and the major secondary endpoint was size of the largest polyp. A total of 206 randomized FAP patients commenced intervention, of whom 133 had at least 1 follow-up endoscopy and so were included in the primary analysis. Neither intervention significantly reduced polyp count in the rectum and sigmoid colon: aspirin relative risk (RR) = 0.77 (95% confidence interval [CI], 0.54–1.10; versus non-aspirin arms); RS RR = 1.05 (95% CI, 0.73–1.49; versus non-RS arms). There was a trend toward a smaller size of largest polyp in patients treated with aspirin versus non-aspirin—mean 3.8 mm versus 5.5 mm for patients treated one or more years (adjusted $P = 0.09$) and mean 3.0 mm versus 6.0 mm for patients treated more than one year ($P = 0.02$); there were weaker such trends with RS versus non-RS. Exploratory translational endpoints included crypt length (which was significantly shorter in normal-appearing mucosa in the RS group over time) and laboratory measures of proliferation (including Ki67). This clinical trial is the largest one ever conducted in

the setting of FAP and found a trend of reduced polyp load (number and size) with 600 mg of aspirin daily. RS had no clinical effect on adenomas.

Introduction

Somatic mutations in the adenomatous polyposis coli (*APC*) gene are found in most colorectal cancers (CRCs) and many CR adenomas. Germline *APC* defects underlie the disease familial adenomatous polyposis (FAP), which is characterized by the development of thousands of CR polyps beginning typically during puberty. Therefore, FAP patients represent a powerful model for CRC chemoprevention studies.

Consistent evidence of a protective effect of aspirin against CR neoplasia in 27 cohort or case-control studies (1, 2) contrasts with four randomized trials which found only marginal evidence in favour of this benefit (3-6). In a study of 1121 patients with a history of adenoma formation, Baron et al. (4) found that aspirin at 81 mg per day had a small protective effect (adenoma risk ratio [RR] = 0.81; 95% confidence interval [CI], 0.69–0.96), whereas aspirin at 325 mg daily did not (RR = 0.96; 95% CI, 0.81–1.13); the effect of the lower dose was greater on more advanced lesions (RR = 0.59; 95% CI, 0.38–0.92). A randomized placebo-controlled trial of aspirin (325 mg) by Sandler et al. (3) in 635 patients with a previous colorectal cancer found that adenomas developed in 17% of the aspirin group versus in 27% of the placebo group after 1 year ($P = 0.004$). Benamouzig et al. (5) reported that lysine acetylsalicylate treatment resulted in an adenoma RR of 0.73 (95% CI, 0.52–1.04), with a greater effect of 300 mg versus 160 mg of lysine acetylsalicylate and a significantly reduced risk of advanced lesions ($P = 0.01$). Most recently, Logan et al. (6) found that aspirin (300 mg/day) reduced adenoma risk (versus placebo; RR = 0.79; 95% CI, 0.63–0.99) in 939 people who had had an adenoma removed, again with evidence of a greater impact on advanced lesions.

Nine epidemiological studies have investigated the relationship between starch intake and CR neoplasms, with higher starch intakes providing neoplasm reductions in the range of 25%–50% (7). Cassidy et al. reported a significant negative correlation between population starch intakes and colon-cancer incidence (8). Resistant starch (RS) is the sum of starch and the products of starch digestion not absorbed in the small intestine of healthy individuals (9); it undergoes colonic fermentation to short-chain fatty acids including butyrate (10). RS supplementation can improve a number of potential biomarkers of CRC risk including faecal concentrations of total and secondary bile acids, which it lowers (11, 12). The RS product butyrate reduces colonic neoplasia in azoxymethane-treated rats (13), and concentrations of physiological butyrate suppress the *in-vitro* growth of CRC cell lines and induce G1 cell-cycle arrest, terminal differentiation, and apoptosis (14-17), probably reflecting its role as an inhibitor of histone deacetylase. Butyrate and non-steroidal anti-inflammatory drugs (NSAIDs) differ radically in the transcriptome and proteome modifications they produce in tumor cells (17, 18).

The first trial conducted within the Colorectal Adenoma/Carcinoma Prevention Programme (CAPP), the present study (CAPP1) was aimed to test aspirin and RS for preventing adenoma development in adolescents with FAP and for effects on mucosal crypt dimensions and cell proliferation, which are potential biomarkers of CRC chemoprevention.

Materials and Methods

Patient eligibility

Polyposis registry clinicians recruited young male and female patients who met the following major eligibility criteria: An age of 10 and 21 years old and confirmed or a high likelihood of the presence of FAP. FAP status was determined by molecularly confirmed carriage of the FAP-associated *APC* mutation or by the determination of having a high probability of carrying the mutation on the basis of linked DNA markers or the presence of multiple colonic polyps, and/or multiple areas of congenital hypertrophy of retinal pigment epithelium in the context of a known FAP family history. Restricting eligibility to members of families manifesting classical FAP helped ensure homogeneity of disease in our study population. Current NSAID therapy, known aspirin sensitivity, major intercurrent illness, and pregnancy were grounds for exclusion. Advanced FAP was not a reason for exclusion unless surgery was planned within the next 12 months. The eligibility cut-off at 21 years old was based on concerns that continuation beyond this age might risk delaying preventive surgery. All patients were required to provide written consent to participate in the trial; written consent was required from the parents of patients under age 16 years. They were advised strongly to avoid all products containing aspirin or other NSAIDs and to use paracetamol for pain relief.

Trial design

We conducted an international, multicenter, double-blind, randomized trial with four arms: aspirin (600 mg as 2 tablets/d) plus matched placebo, RS (30 g as 2 sachets/d in a 1:1 blend of potato starch and high amylose maize starch [Hylon VII]) plus matched placebo, aspirin plus RS, and placebo plus placebo; this trial employed a 2×2 factorial design. All polyposis registries and clinics in Europe were invited to participate in the CAPP1 Study. Our accrual goal was 208 patients, 52 in each of the four intervention arms.

Randomization was performed centrally at Leeds University via a blocked randomization scheme with a block size of 16 so that each set of 16 recruits contained 4 persons within each of the 2×2 trial arms. The blocked randomization was stratified at the level of geographical regions recruiting sufficient numbers of participants in order to avoid confounding of trial results due to geographical differences (e.g., regional diet); the regional strata were as follows: United Kingdom, Scandinavia, Northern Europe and southern Europe. Last, if siblings were enrolled, we assigned each member of such family groups the same combination to remove the potential for package mix-ups within the family. The duration of intervention was from 1 to a potential maximum of 12 years, with a scheduled annual clinical examination including endoscopy. Patients were advised of their option to leave intervention after each annual examination but were invited to remain on intervention (up to and including age 21 years).

The primary trial endpoint was the proportion of patients with an increased polyp count in the rectum and sigmoid colon after intervention. A major secondary endpoint was size of the largest polyp, which was chosen as another quantifiable and objective measure of disease severity. Given the multiple, international centers participating in this trial, it was not feasible to influence the clinical decision on whether the largest polyp was removed or left *in situ* nor to tattoo any polyps for review at a later examination. We also assessed crypt dimensions. Secondary laboratory endpoints included proliferative-state assessments of 1) crypt-cell proliferation (CCP) measured by direct counting of mitoses and of 2) indices of proliferation measured using antibodies against proliferating-cell nuclear antigen (PCNA) and Ki67.

The RS dose was based on the maximum easily tolerated doses and doses used previously in short-term intervention studies with CRC biomarkers as endpoints (19, 20). Aspirin and its matched placebo were supplied by Bayer (Leverkusen, Germany); the matched placebo was a lactose tablet (packaged at the pharmacy of Freeman Hospital in Newcastle). RS and its matched placebo were supplied by the National Starch and Chemical Company (Bridgewater, New Jersey); the matched placebo was 30 g/d of digestible corn (maize) starch. Children under 45 kg or under 12 years of age took half doses.

The trial was conducted in accordance with principles of the Declaration of Helsinki, and each study center was required to get the protocol, including the final version of the patient-information and informed-consent form, approved by its ethics committee.

Endpoint ascertainment

Endoscopists counted the actual number of polyps in the rectum and sigmoid colon if there were 10 or fewer and provided an estimate (11–15, 16–20, 21–30, 31–50, 51–100, >100) when more numerous. We also collected data on the total number of polyps (rectum and sigmoid, ascending, transverse, and descending colon), which presented a challenge because of differing endoscopy policies and the challenge of the total number of polyps in an FAP patient, which can run into the thousands. When the study was initiated, many centers used sigmoidoscopy under sedation to monitor young people with FAP and usually avoided polyp removal unless a polyp became very large or appeared to be advanced. Some centers relied on paediatric endoscopists who tended to prefer full colonoscopy under anaesthetic. A diagrammatic form was used to clarify polyp-count (actual or estimated) instructions and to invite the endoscopist to mark the maximum extent of examination. The size of the largest polyp was recorded on the form (estimated by comparing the polyp with open 5-mm biopsy forceps).; We also requested all centers to record a withdrawal video of the rectum. If it was necessary to remove polyps, we asked that a recording be made before and after the removal. We specified rectal videos because we expected higher compliance among busy endoscopists with a rectal versus a more-comprehensive, more-time-consuming video. At least two withdrawal recordings in different perpendicular planes (i.e., at 90°) or with views taken from 10, 2, and 6 o'clock and starting at 20 cm from the anal verge were requested. At least twice during the recording, 5-mm forceps were opened near a polyp to assess the size of polyps and to provide a scale for the views. Almost all endoscopists complied with the request for open-forceps reference images, but there was considerable variation in extent of recording, with some offering a full-withdrawal recording rather than only imaging the rectum. The video recordings were scored (better, worse, or same) by two experienced endoscopists (SB and RKSP) blinded to intervention and the time point of examination (baseline, first year, second year, etcetera).

For assessing proliferative-state endpoints, six 5-mm mucosal biopsies were obtained from macroscopically normal mucosa from 5 to 15 mm from the anal verge; two biopsies were fixed in 75/25 absolute alcohol/glacial acetic acid for CCP, two were fixed in methacarn fixative (60 methanol:30 chloroform:10 glacial acetic acid) for PCNA immunostaining, and two in 10% neutral buffered formalin for determining Ki67 via MIB-1 immunostaining; these samples were transported to Newcastle University for processing. On receipt, CCP samples were transferred to 70% alcohol for long term storage.

Data and safety monitoring

Located in Newcastle University, the CAPP Operations Center housed the CAPP Principal Investigator (JB), Study Manager, Research Associate/Recruiter, technician, and pharmacist and coordinated the activities of the formal, independent CAPP Data Monitoring Committee (DMC) and the CAPP Steering Committee, which comprised multidisciplinary members to

help in guiding the trial. The Operations staff coordinated day-to-day administration of the study, including dealing with study inquiries, distributing intervention packs, and collecting surveillance data including the hand-marked colorectal forms (which recorded the number and location of adenomatous polyps and size of the largest polyp in the examined colorectal segments), video recordings, and biopsy material for storage and processing. The Operations Center also offered study sites the option of genetic testing for the FAP-associated *APC* mutation in samples obtained from prospective patients. All trial data were transmitted by the study sites to the Operations Center, where they were entered into a computerized study database and transmitted ultimately to the trial Statistical Center at Leeds University for analysis; prior to the end of study, only randomization data were held at the CAPP Statistical Center in Leeds. The CAPP Study Manager and principal investigator visited study sites frequently on an ad hoc basis, conducting chart reviews and other procedures necessary to ensure the integrity of the data and safety of patients. The CAPP statistical team at Leeds University annually reported the trial data to the DMC, chaired by Professor Doug Altman (London, Cancer Research UK), for safety and efficacy review. The DMC was responsible for interrupting the trial if and when warranted by statistically significant preliminary results. All of these operational procedures were facilitated by the long-standing collaborative association of our sites as members of a trials consortium called the Leeds Castle Polyposis Group, one of the two research communities which gave rise to the International Society for Gastrointestinal Tumours (InSiGHT – www.insight-group.org)

Compliance

To maintain interest in study participation, recruitment-site personnel were asked to contact each study patient at least once every six months to coincide with a delivery of study tablets and sachets to the patient. Unused tablets and sachets were collected, counted, and recorded by the recruiters to assess compliance with study interventions. The Operations Center sent study tablets and sachets once a month to the study sites so as to maintain regular, monthly contact with the sites; the Center also provided patients with regular updates of study progress to maintain enthusiasm.

Laboratory methods

We assayed proliferative states via three techniques (21) so as to assure reliable results for this important aberration. We used *a*) a crypt-microdissection method in tissue fixed in alcohol/acetic acid to provide estimates of CCP because this method is technically robust and *b*) two methods that applied antibodies to sections of formalin-fixed tissue for identifying dividing cells marked by the antibodies against PCNA and Ki67. As described earlier in Methods, six variously fixed biopsies were taken from normal mucosa near the anal verge at the baseline and annual examinations. When required for histological analysis to determine CCP, samples were re-hydrated, stained with Schiff's reagent, and microdissected to enable direct counts of total numbers (and location) of mitoses in whole crypts (22). The numbers of mitotic cells in each tenth of the crypt by length were recorded; crypt compartments were numbered from 1 (base) to 10 (luminal surface). Formalin-fixed biopsies were paraffin-embedded and sectioned routinely prior to immunohistochemical staining by MIB1 to detect Ki67 (22) and by PC10 to detect PCNA.

Crypt width and length were measured in the microdissected specimens and formalin-fixed tissue sections via a graticule in the microscope eyepiece and were standardized via a reference slide. Results from 10 crypts were averaged for each biopsy assessed.

Statistical methods

The study was designed to detect a statistically significant difference in the proportion of patients with an increased polyp number in the rectum and sigmoid colon in the aspirin

(versus the non-aspirin) group or in the RS (versus the non-RS) group at the end of intervention (versus at baseline). The total number of polyps in the rectum and sigmoid colon (prior to any polypectomy) at all endoscopies subsequent to baseline was the outcome measure, i.e., the dependent variable using a random effects model. Data for the total number of polyps seen in the rectum and sigmoid colon were available on all participants for all colonoscopies.

We included the secondary endpoint of total number of polyps throughout the colon (adjusted for the extent of endoscopy to account for the variable completeness of endoscopy) so as to make more complete use of collected data. Variability in local policy over extent of endoscopy meant that polyps were counted, or estimated when too dense, in differing numbers of colorectal segments. We allowed for this variability by adjusting models for extent at all endoscopies subsequent to baseline, including it as an independent variable in the random effects models. Prior to the random effects modelling, linear regression was performed so that total number of polyps at baseline endoscopy was the dependent variable and extent at baseline endoscopy was the independent variable. Adjusted values were calculated from the linear regression, i.e., we computed the difference between the observed number of polyps at baseline and the average number of polyps for that extent at baseline endoscopy. This adjusted number of polyps at baseline was then included in the random effects model as an independent variable.

This was a 2×2 factorial analysis that compared the two aspirin arms combined (aspirin plus RS and aspirin plus placebo) with the RS-plus-placebo and placebo-plus-placebo arms combined, and compared the two RS arms combined (RS plus aspirin and RS plus placebo) with the aspirin-plus-placebo and placebo-plus-placebo arms combined. We estimated an event rate of 40% in non-responding patients, i.e., that 40% of the patients in that group would have an increased polyp number (rectum, sigmoid colon) at the end of intervention, and an intervention effect of 50% fewer patients (i.e., a total of 20%) developing an increased number in the responsive intervention group, based on the average effect recorded in the published observational studies (23). Due to the suggestion in some of these studies that the effect was greater with prolonged use, the present study was designed to allow participants to remain on study for as long as they could tolerate the interventions. The final sample size estimate of 208 patients, 52 in each of the four arms of the factorial design, was based on early data indicating that almost all patients had detectable pathology and was designed to detect the anticipated intervention effect with an 80% power and alpha level of 0.025.

Major, prespecified secondary analyses included the size of the largest polyp at the end of intervention and assessed in the subset of patients who remained on study for > 1 year; these patients were anticipated to be more likely to be fully compliant and to respond to an active intervention. Measurements of crypt length and width, hemicypt cell count, and proliferation in normal mucosal biopsies also were secondary endpoints; these endpoints were considered exploratory since there were no prior data on potential effects on which to base power calculations.

Eight outcome measures were analyzed: three clinical endpoints (number of rectal and sigmoid polyps, largest polyp size [mm], and overall polyp number) and five exploratory translational endpoints (mean total CCP, crypt width, crypt length, the mean number of MIB1-positive cells per crypt, and the mean number of cells per hemicypt). All but the last variable were log transformed before analysis; for log-transformed outcome measures, the exponent of the intervention coefficient was taken to indicate the ratio of the outcome measure in treated to untreated patients; a ratio of 1.0 indicates no differences between treated and untreated patients.

Analysis of variance (ANOVA) and Pearson Chi-squared tests were carried out to compare baseline measures. Associations between the baseline measures and age and sex were tested using two-sided t-tests, Chi-squared tests, and Spearman's correlations. Spearman's correlation coefficients were calculated for all pair-wise combinations of the continuous baseline measures. Differences in final largest polyp size between the four intervention groups were investigated using linear regression. Modeling involved estimation of random effects, linear models, and generalized estimating equation (GEE) logit models to identify main effects and possible interactions between intervention and time. The primary analyses compared the two arms containing aspirin with the two arms not containing aspirin and separately compared the two arms containing RS with the two arms not containing RS. The outcome measures in these models comprised all results obtained after entry endoscopy, and all models were adjusted for entry data and time on the intervention (years). In addition, the random-effects models for the total number of polyps were adjusted for age and extent, i.e., the proportion of the colorectum examined. The total polyp number at entry was adjusted for the extent of endoscopy via adjusted values from linear regression; in specific, we computed the difference between the observed number of polyps and the average number of polyps for that extent of endoscopy. This residual number formed the adjusted total of polyps at entry endoscopy. In analyses of numbers of polyps, the number of polyps which were removed at any endoscopy other than the last was added to the total number of polyps recorded at the following endoscopy.

We tested differences between interventions in results from video analysis with Fisher's exact test. All analyses were carried out using STATA version 8 (StataCorp. 2003. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation), and probabilities less than 0.05 were considered significant.

Results

Patient characteristics

Recruitment to this trial took place in 12 international centers from June 1993 until April 2002. Initially 227 young people with intact colons were recruited into the study and 206 of these started the intervention (Fig. 1). Fifty-nine percent (133/227) had a baseline and at least one other endoscopy and were therefore eligible for data analyses. At baseline, these patients ranged in age from 10 to 21 years old, with a mean age of 18 years, and half were female (Table 1). Patients were offered the option of leaving study at one year but were invited to remain on study past one year, some remaining on intervention for up to 7 years before the study ended. The study was approved by the relevant ethical committees in the participating countries. All recruits provided informed consent for their participation in the study and the provision of tissue samples.

Withdrawal rates in each intervention group were compatible with random loss [$\chi^2(3) = 5.0$; $P = 0.3$]. For the 94 patients excluded from analysis, there was a non-significant difference in age at "dropout" between the four intervention groups (ANOVA, $P = 0.06$). Of the patients included in the final analysis, 57% (76/133) had two colonoscopies, 23% (30/133) had three colonoscopies, 11% (15/133) had four, and 9% (12/133) had 5–8 colonoscopies. No polyps were found in 15% of the colonoscopies; 57% of the colonoscopies went further than the sigmoid colon.

At baseline, the four intervention groups were well matched with regard to sex [$\chi^2(3) = 6.2$, $P = 0.1$], age (ANOVA, $P = 0.90$), or any of the polyp and crypt parameters shown in Table 1. Younger patients tended to have more polyps at study entry (data not shown). At entry endoscopy, 41% of patients had one or more polyps removed; these patients tended to be

older (mean age of 19 years) than those who did not have polyps removed (mean age of 16 years; two-sided t-test, $P = 0.06$).

Polyp assessments

After a median intervention period of 17 months (range 1 to 73 months), the risk of an increased polyp number in the rectum and sigmoid colon (primary endpoint) was not significantly reduced in either the aspirin or RS group (versus its counterpart group), with relative risks of 0.77 (aspirin; 95% CI, 0.54–1.10; versus non-aspirin) and 1.05 (RS; 95% CI, 0.73–1.49; versus non-RS group; Table 2). The diameter of the largest polyp (major secondary endpoint) detected by the endoscopist at the end of intervention tended to be smaller in the aspirin group ($P = 0.05$ and $P = 0.09$ after adjusting for baseline measures; Table 3). The planned subgroup analyses of patients who elected to continue on study for more than one year found a significant reduction in the size of the largest polyp in the aspirin versus non-aspirin group ($P = 0.02$, adjusted for baseline; Table 3). We found an absence of polyps in the majority of our blinded review of rectal videos (both at baseline and during intervention), even though there were adenomas in the colon, so that most of the annual rectal videos in the four intervention categories received the same score as did the baseline video. The risk of an increased total number of polyps in all examined segments of the colorectum (data not shown for this total number) was not reduced in either intervention group, with relative risks of 0.97 (aspirin; 95% CI, 0.65–1.43; versus non-aspirin) and 0.96 (RS; 95% CI, 0.65–1.42; versus non-RS).

Crypt dimensions in macroscopically normal rectal mucosa

Relative risks of effects of intervention on crypt width and length are shown in Table 2. Mean crypt length decreased significantly over time on study in the two combined RS groups, compared with the two combined non-RS groups ($P < 0.0001$ for interaction), in a model of the interaction between intervention and time (Fig. 2).

Proliferation-state assessments (CCP, Ki67, PCNA)

Histological examination of microdissected crypts from biopsies of apparently normal mucosa indicated increases in total CCP of 28% ($P = 0.12$) in the RS versus non-RS group and 37% ($P = 0.05$) in the aspirin versus non-aspirin group (Table 2). Ki67 results are also indicated in Table 2 (“Number of MIB1-positive cells”). Although both the microdissection-based method for CCP and the MIB1-staining method for Ki67 worked well during trial, the PCNA-based method proved to be unsuitable for a dispersed multi-center study such as CAPP1; the prolonged and variable immersion of samples in formalin due to differing durations of transport made PCNA recovery very problematical; and the PCNA results were considered to be too unreliable for analysis.

Toxicity

No serious adverse effects were recorded. Some bloating was reported among RS takers. One participant in the aspirin/RS arm withdrew because of persistent nose bleeds. There were no other reports of bleeding or of cardiovascular or cerebrovascular events. The most common reason cited for withdrawal from study was difficulty in including starch in the habitual diet. There was no statistically significant difference between starch and its matching placebo or aspirin and its matching placebo in rates of withdrawal.

Discussion

This trial of aspirin (600 mg/d) and RS (30 g/d) in preventing adenoma occurrence in young people (mean age 18 years) with FAP is the largest clinical trial ever conducted in this

setting. There was a non-significant trend of a reduced number of polyps in the rectum and sigmoid colon (primary endpoint) in the overall aspirin group (aspirin plus placebo and aspirin plus RS) versus the non-aspirin group at the end of intervention (Table 2). There also was evidence that the size of the largest polyp (secondary endpoint) was reduced in the overall aspirin versus the overall non-aspirin group (Table 3). Furthermore, among those treated for more than one year, the diameter of the largest polyp recorded in the aspirin group (3.0 mm) was only half that recorded in the non-aspirin group (6.0 mm; $P = 0.02$). Results of RS are discussed later.

Previous randomized trials (3-6,) support the view that long-term (1-3 years) aspirin ingestion (81 mg/d-325 mg/d) results in a small but significant reduction in colonic adenoma formation in older persons with previous sporadic adenomatous polyps or CRC. In contrast, the CAPP2 Study (which used interventions similar to those in the present CAPP1 Study) revealed no apparent beneficial impact on colorectal neoplasia (largely adenomatous polyps) of either aspirin at 600 mg or RS at 30 g daily in people with Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) after intervention for 29 months (24). Subsequent follow-up of participants in the CAPP2 Study suggests an impact on subsequent cancers despite the lack of effect on adenoma formation (25). The modest efficacy of aspirin in intervention studies reported to date contrasts with the very substantial evidence from observational epidemiological studies showing an approximately 50% reduction in risk of CRC among regular aspirin takers over prolonged periods (26). These data suggest that aspirin may inhibit cancer in ways other than through inhibiting adenoma growth and development.

Several studies since the CAPP1 study was initiated lend support to the chosen interventions; the large cohort study European Prospective Investigation into Cancer and Nutrition (EPIC) (27, 28) demonstrated a lower CRC risk in people with a higher dietary fiber intake. It is probable that a higher fiber intake is associated with a higher intake of RS. The NSAID celecoxib has been shown to inhibit adenoma development in patients with previous adenomas (29, 30), although concurrent low-dose aspirin use had no additional impact. A study involving one of our senior authors (RKSP) drew on early experience from CAPP1 and demonstrated an inhibitory effect of celecoxib on adenoma development in FAP (31). One of the potential limitations of the CAPP1 Study was that data on polyp numbers and sizes were collected by multiple endoscopists at several centers during a period of substantial improvements in endoscopy performance. These issues likely increased the variation in estimates of polyp burden and so reduced the ability to detect effects of the interventions. The Steinbach et al. study (31) avoided these problems by using only two specialist endoscopy teams.

Assuming that more-compliant patients would volunteer to remain on study after the first planned exit opportunity (at one year), we planned secondary analyses of patients who remained on study for more than one year. These analyses revealed a significantly beneficial effect of aspirin on polyp size (Table 3). The impact of aspirin in reducing the recorded size of the largest polyp is a finding of potential clinical importance since it would imply an effect on disease progression rather than initiation. There has been considerable focus on cyclooxygenase 2 (COX-2) inhibition as a mechanism for colorectal cancer prevention, but the COX inhibitory properties of aspirin are largely against COX-1. Aspirin has effects on other pathways of importance in tumorigenesis, however; for example, Stark et al. (32) showed that aspirin suppresses nuclear factor kappa B (NFκ-B)-driven transcription and enhances apoptosis. We have demonstrated *in vitro* inhibition of new blood-vessel formation by physiological concentrations of salicylate (33). Such effects might prevent small adenomas from progressing to malignancy; even a modest reduction in the volume of large polyps will reduce the number of cells exposed to subsequent genetic alterations leading to

malignant transformation. The evidence of an aspirin impact on the progression of neoplasia is in keeping with protective effects against colon cancer more than a decade after aspirin therapy stopped in cardiovascular prevention trials of the 1980s; these findings were extended by recent analyses of cardiovascular trials of low-dose aspirin that revealed a similar, but smaller, delayed effect on colorectal cancer incidence and cancer death (34).

There was no detectable effect of RS on number of polyps in the rectum and sigmoid colon in the primary analysis. Secondary findings indicated that longer-term use of RS was associated with a significant reduction in crypt length in normal-appearing mucosa. This discovery is of biological interest and may provide an independent indicator of compliance with the intervention. There was no evidence that RS supplementation had any adverse effect on adenoma risk. Epidemiological studies suggest that higher starch diets (richer in RS) are associated with reduced CRC risk, and there is strong evidence for antineoplastic effects of butyrate, a major short-chain fatty acid produced in the colon from bacterial degradation of RS. There have been reports, however, of increased neoplastic risk in rodents given very large RS doses (much greater than those used in human studies; ref. 17). Although we assessed both aspirin and RS for effects on the total number of polyps in all examined segments of the colorectum, multicenter and international variability in the extent of colon examined beyond the sigmoid segment made results of these analyses highly variable and difficult to interpret despite our rigorous efforts to account for this variability.

The CAPP1 Study in isolation does not provide sufficient evidence to recommend long-term use of aspirin in FAP patients. It might be argued, however, that seen in the light of recent publications suggesting a long term benefit in cancer prevention (34), aspirin is worthy of further evaluation in FAP patients who retain segments of the colorectum, particularly in the context of concern over the potential side effects of selective COX-2 inhibitors.

Although aspirin and RS had limited (or no) demonstrable effect in CAPP1 on polyp formation in FAP, it remains to be established whether these agents are effective in other settings. The CAPP2 Study tested the effect of similar interventions in an older, genetically susceptible population with pathological mutations in mismatch repair genes (Lynch syndrome or HNPCC). After 29 months of intervention, there was no significant effect of either intervention agent on colorectal neoplasia (largely adenomatous polyps). Recent results from long-term follow-up, however, suggest effects on carcinoma occurrence after cessation of the intervention. These results are consistent with the conclusion that the anti-neoplastic effects of aspirin intervention may take many years to appear.

The CAPP1 study successfully recruited and retained 113 participants with FAP, but many challenges have made this low-cost international approach based on FAP registries less attractive than was originally hoped. These challenges include the young age of the group under investigation; variable clinical practices in different countries meaning that colonoscopies were highly variable in terms of the extent of colonic investigation; and successful follow-up when working with so many different clinical groups, each of which could recruit only limited numbers of participants because of the low prevalence of the disease. Nevertheless, the genetically susceptible population must remain of primary interest given their capacity to provide a model system for disease processes usually too lengthy to be studied in the prevention setting.

Footnotes

Corresponding Author: Prof. Sir John Burn MD Institute of Human Genetics, Newcastle University, Centre for Life Newcastle upon Tyne NE1 3BZ Phone: +44 191 241 8734; Fax: [+44 191 241 8666]; john.burn@ncl.ac.uk.

¹⁵Investigators participating in CAPP1 are listed in the Appendix. CAPP originally stood for Concerted Action Polyp Prevention of the European Union and now stands for Colorectal Adenoma/Carcinoma Prevention Programme.

Authors contribution statements:

I declare that I participated in the design of the CAPP1 Study, supervised the randomisation process and the statistical analysis, and participated in the writing of the manuscript. I have seen and approved the final version. I have no conflicts of interest.

Prof D Timothy Bishop

I declare that I participated in the “CAPP1” study in the role of manager. I have seen the final version of the submitted paper. I know of no conflicts of interest. I was funded for this study by Cancer Research UK, and from a BIOMED grant.

Pamela Dorothy Chapman

“I declare that I participated in the statistical analyses and writing of the statistical methods and results section and that I have seen and approved the final version. I have no conflicts of interest”

Faye Elliott

I declare that I participated in the study as member of scientific committee recruiting and following FAP patients according the protocol guidelines. Moreover I affirm don't have any conflict of interest and that I have seen and approved the final version of the submitted manuscript

Lucio Bertario MD

I have seen and approve of the final version of the paper. I declare that I contributed to the original conception of the study and participated in recruitment of volunteer patients, as well as contributed, in a minor way, to scientific thinking during the course of the study. I have seen and approved the final version. I have no conflicts of interest relevant to this paper.

Prof Malcolm G Dunlop MD

I declare that I participated in the CAPP1 study as a member of the working party involved in devising the study and in recruiting patients from my regional genetic service. I have seen and approved the final version. I have no conflict of interest.

Prof Diana Eccles MD

I declare that I contributed to the study “a randomised placebo controlled trial of aspirin and/or resistant starch as chemo preventative agents in young people with familial adenomatous polyposis: The CAPP1 Study” by providing patients and taking the appropriate specimens, and that I have seen and approved the final version

Dr A Ellis

I contributed to study concept, patient recruitment reading manuscript and approving final version

Prof D Gareth Evans

I hereby declare that I participated in the CAPP1 study by performing mutation analysis of the hereditary colorectal cancer patients who joined the trial. Moreover, I have seen and approved the final version of the submitted manuscript. I do not have any conflicts of interest.

Prof. Dr. Riccardo Fodde, PhD

I declare that I contributed to the CAPP1 study by providing patients. I have seen and approve the final version of the paper. I have no conflicts of interest.

Prof. Eamonn Maher

I declare that I participated in the study “A randomised placebo controlled trial of aspirin and/or resistant starch as chemopreventative agents in young people with familial adenomatous polyposis: The CAPP1 Study” and that I have seen and approved the final version. I have no conflicts of interest regarding this study.

Prof D med. G. Möslein MD

Re: “A randomised placebo controlled trial of aspirin and/or resistant starch as chemopreventative agents in young people with familial adenomatous polyposis: The CAPP1 Study” I declare that I participated in the protocol development, recruitment of participants and interpretation of the results and that I have seen and approved the final version. I have no conflicts of interest.

Hans F A Vasen MD

“I Julie Coaker declare that I performed the laboratory analysis of all biopsies for the CAPP1 study and that I have seen and approved the final version”.

Julie Coaker

I declare that I participated in the conception and design of the study and along with Dr Bülow performed all video analyses. I have seen and approved the final version. I have no conflicts of interest.

Prof Robin Phillips MD

I hereby declare that I participated in planning of the study and data capture, and that I have seen and approved the final version of the manuscript. I have no conflicts of interest.

Dr Steffen Bülow MD

I declare that I participated in the design and management of the study, supervised the laboratory measurements, contributed to data interpretation and writing the manuscript and that I have seen and approved the final version. I have no conflicts of interest.

Prof. John C Mathers PhD

Disclosure of Potential Conflicts of Interest

No conflicts of interest were disclosed.

Acknowledgments

Role of the Funding Source

In this trial the role of the funding sources was strictly financial. They had no input into the study design, data collection, analysis and interpretation in writing of the report and in the decision to submit the paper for publication.

Grant Support

This work was supported in part by grants from the European Union Biomedical Program Cancer Research UK, and the UK Medical Research Council.

Appendix

The trial was initiated under the European Union Biomed 1 project with support from the Imperial Cancer Research Fund (now Cancer Research UK). Additional support was received from MRC project funding, the Bayer Corporation and National Starch & Chemical Company. The following UK colleagues not listed among the authors led contributions from their centre: Aberdeen - Neva Haites, Bristol - Peter Lunt, Cambridge - Jane Koch, Leeds - Gwen Turner, Leicester - Richard Trembath, Manchester - Fiona Lalloo, Sheffield - Oliver Quarrell, and London - Vicky Murday.

Non UK centres, with lead contributors, were Amiens - Catherine Lenaerts, Budapest – Andrew Czeizel, Coimbra - Julio Leite, Lisbon – Paulo Fidalgo, Pamplona - Angel Alonso, Naples - Alfonso Tempesta, Szczecin - Jan Lubinski, Stockholm - Helena Akerbrant & Rolf Hultcrantz, Vilnius - Narimantas Samalavicius, Zurich - Rainer Hurlimann

John Cummings of the MRC Dunn Nutrition Unit (now at Dundee University) played a major supportive role in the establishment of the CAPP programme. The following staff played a key role in delivery of the project: Olive Armstrong, Lynn Reed, Beccy Dixon, Lois Thomas and the support staff of the contributing centres. We are especially grateful to the participants and their families who made great sacrifices to support this research project.

References

1. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. *The Lancet Oncology*. 2009; 10(5):501–7. [PubMed: 19410194]
2. Din FV, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. *Gut*. 2010 N TE.
3. Sandler RS, Halabi S, Baron JA, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer. *The New England Journal Of Medicine*. 2003; 348(10):883–90. [PubMed: 12621132]
4. Baron JA, Cole B, Sandler RS, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. *The New England Journal Of Medicine*. 2003; 348(10):891–9. [PubMed: 12621133]
5. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial1. *Gastroenterology*. 2003; 125(2):328–36. [PubMed: 12891533]
6. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and Folic Acid for the Prevention of Recurrent Colorectal Adenomas. *Gastroenterology*. 2008; 134(1):29–38. [PubMed: 18022173]
7. Young G, Le Leu RK. Resistant Starch and Colorectal Cancer. *Journal of AOAC International*. 2004; 87:775–86. [PubMed: 15287679]
8. Cassidy A, Bingham SA, Cummings JH. Starch intake and colorectal cancer risk: an international comparison. *BrJCancer*. 1994; 69:937–42.

9. Asp N-G, vA JMM, Hautvast J,G,A,J. Nutritional implications of resistant starch. *Nutrition Research Reviews*. 1996; 9:1–31. [PubMed: 19094263]
10. Scheppach W, F C, S M, K H. Effect of starch malabsorption on fecal short-chain fatty acid excretion of man. *Scand Journal of Gastroenterol*. 1988; 23:755–9.
11. Hylla S, Gostner A, Dusel G, et al. Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. *AmJClinNutr*. 1998; 67:136–42.
12. Grubben MJAL, van den Braak CMM, Essenberg M, et al. Effect of Resistant Starch on Potential Biomarkers for Colonic Cancer Risk in Patients with Colonic Adenomas. *DigDisSci*. 2001; 46(4): 750–6.
13. D'Argenio G, Cosenza V, Cave MD, et al. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. *Gastroenterology*. 1996; 110(6):1727–34. [PubMed: 8964397]
14. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer. *IntJCancer*. 1993; 55:498–505.
15. Heerdt B, Houston M, Augenlicht L. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. *Cancer Res*. 1994; 54(12): 3288–93. [PubMed: 8205551]
16. Siavoshian S, Segain J-P, Kornprobst M, et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. *Gut*. 2000; 46(4):507–14. 10.1136/gut.46.4.507. [PubMed: 10716680]
17. Mariadason JM, Corner GA, Augenlicht LH. Genetic Reprogramming in Pathways of Colonic Cell Maturation Induced by Short Chain Fatty Acids: Comparison with Trichostatin A, Sulindac, and Curcumin and Implications for Chemoprevention of Colon Cancer. *Cancer Res*. 2000; 60(16): 4561–72. [PubMed: 10969808]
18. Williams EA, Coxhead JM, Mathers J. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. *Proceedings of the Nutrition Society*. 2003; 62:107–15. [PubMed: 12740065]
19. van Munster IP, Tangerman A, Nagengast FM. Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. *DigDisSci*. 1994; 39(4):834–42.
20. Grubben M, Braak CVD, Essenberg M, et al. Effect of Resistant Starch on Potential Biomarkers for Colonic Cancer Risk in Patients with Colonic Adenomas: A Controlled Trial. *DigDisSci*. 2001; 46(4)
21. Goodlad RA, Levi S, Lee CY, Mandir N, Hodgson H, Wright NA. Morphometry and cell proliferation in endoscopic biopsies: evaluation of a technique. *Gastroenterology*. 1991; 101(5): 1235–41. [PubMed: 1936793]
22. Mills SJ, Mathers JC, Chapman PD, Burn J, Gunn A. Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. *Gut*. 2001; 48:41–6. [PubMed: 11115821]
23. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the Risk of Colorectal Cancer in Women. *N Engl J Med*. 1995; 333(10):609–14. [PubMed: 7637720]
24. Burn J, Bishop DT, Mecklin J-P, et al. Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. *N Engl J Med*. 2008; 359(24):2567–78. [PubMed: 19073976]
25. B J. Aspirin prevents cancer in Lynch syndrome. *European Journal of Cancer Supplements*. Sep. 2009 ;1. 2009.
26. U.S. Preventive Services Task Force*. Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. *AnnInternMed*. 2007; 146(5):361–4.
27. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. *The Lancet*. 2003; 361(9368):1496–501.
28. Bingham S. The fibre-folate debate in colo-rectal cancer. *Proceedings of the Nutrition Society*. 2006; 65(1):19–23. [PubMed: 16441940]

29. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the Prevention of Sporadic Colorectal Adenomas. *N Engl J Med*. 2006; 355(9):873–84. [PubMed: 16943400]
30. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial. *Cancer Prev Res*. 2009; 2(4):310–21.
31. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *The New England Journal Of Medicine*. 2000; 342(26):1946–52. [PubMed: 10874062]
32. Stark LA, Dunlop MG. Nucleolar Sequestration of RelA (p65) Regulates NF- κ B-Driven Transcription and Apoptosis. *Mol Cell Biol*. 2005; 25(14):5985–6004. [PubMed: 15988014]
33. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. *FASEB J*. 2006; 20(12):2009–16. 10.1096/fj.06-5987com. [PubMed: 17012253]
34. Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *The Lancet*. 2010; 376(9754):1741–50.




Fig. 1.
CAPP1 consort diagram.




Fig. 2. Mean length of microdissected crypts over time on study in patients of the resistant starch (RS) group (RS plus aspirin placebo, RS plus aspirin) or of the non-RS group (aspirin plus RS placebo, aspirin placebo plus RS placebo). Crypts tended to lengthen with time on study for the non-RS group, whereas they shortened in the RS group (P -value for interaction < 0.0001).

Table 1

Patient characteristics

Baseline measures (range of values)	Number	Intervention (N) *				P-value
		RSP/AP (41)	RS/AP (30)	A/RSP (31)	A/RS (31)	
Age	133	18.2 (7.8)	17.9 (10.8)	17.2 (6.9)	18.8 (7.9)	0.90 $\chi^2(3)=6.2$, p=0.10
Sex	66	41	30	31	31	
	65	19 (46.3)	21 (70.0)	12 (41.4)	14 (45.2)	
	131	22 (53.7)	9 (30.0)	17 (58.6)	17 (54.8)	
		41 (100)	30 (100)	29 (100)	31 (100)	
Number of endoscopies	76	20	19	21	16	
	30	12	3	3	12	
	15	4	5	4	2	
	8	4	2	3	1	
	1	1	1	31	31	
	2	41	30			
	1					
	133					
Polyp data						$\chi^2(3)=4.8$, p=0.18
At least 1 polyp found	13	1 (2.4)	5 (17.9)	3 (10.0)	4 (13.3)	
Number of polyps in the rectum and sigmoid colon (0, 200)	116	40 (97.6)	23 (82.1)	27 (90.0)	26 (86.7)	
Total number of polyps (0, 425)	129	41 (100)	28 (100)	30 (100)	30 (100)	0.53 [†]
Size of largest polyp (mm) (0.5, 50)	129	29.8 (43.0)	29.7 (52.5)	22.7 (32.3)	25.6 (44.4)	0.60 [†]
	110	56.7 (86.4)	63.8	44.5 (90.5)	43.1 (76.2)	0.63 [†]
		41	(115.6)	30	30	
		6.1 (8.2)	28	4.0 (2.5)	4.3 (2.4)	
		38	4.2 (2.7)	27	24	
			21			
Crypts						0.16 [†] 0.27 [†] 0.27 [†]
Crypt width (74.2, 199.7)	113	121.5 (21.6)	110.7	116.8 (24.1)	111.5 (17.3)	
Crypt length (290.4, 765.1)	112	35	(20.3)	25	29	
Mean total CCP (0.2, 37.9)	113	499.4 (84.4)	24	494.8 (75.6)	498.6 (69.1)	
		35	467.3	25	28	
		5.3 (4.9)	(92.9)	7.5 (6.1)	6.1 (4.2)	
		35	24	25	29	
			6.1 (7.8)			
			24			

* Raw means presented.

[†] Log transformed measures used in the tests.

Table 2

Relative risks (RelRs) and 95% confidence intervals (CIs) from 12 univariate models^{*} estimating the effect of intervention by outcome measure

Outcome measures	No. of obs (no. of patients)	RS versus non-RS		Aspirin versus non-aspirin	
		RelR [‡] (95% CI)	P-value	RelR (95% CI)	P-value
Total number of polyps in rectum and sigmoid	215 (116)	1.05 (0.73, 1.49)	0.80	0.77 (0.54, 1.10)	0.16
Crypt width	95 (58)	1.03 (0.93, 1.13)	0.60	0.95 (-0.15, 0.04)	0.28
Crypt length	95 (58)	1.01 (0.93, 1.09)	0.86	1.08 (1.00, 1.16)	0.04
Mean total CCP	95 (58)	1.28 (0.94, 1.73)	0.12	1.37 (1.00, 1.86)	0.05
Mean number of MIB1-positive cells [‡]	116 (78)	1.02 (0.89, 1.16)	0.82	0.99 (0.87, 1.14)	0.93
Hemicyrpt cells [‡] §	116 (78)	-0.82 (-5.05, 3.42) [§]	0.71	3.67 (-0.55, 7.90) [§]	0.09

^{*} All models adjusted for first result and time on intervention (years).

[‡] Estimated as the exponential coefficient of the intervention effect in the random effects model.

[‡] Adjusted for calendar time to account for possible effect of differences in storage time of these samples before analysis; MIB1 is the antibody used in staining for Ki67.

[§] Variable not logged, coefficient not exponentiated.

Table 3

Mean size of largest polyp by intervention group at baseline and at the end of intervention with aspirin (A) and/or resistant starch (RS)

	Mean Size of largest polyp* (N)							
	Four intervention group comparison [†]				Aspirin comparison		Starch comparison	
	RSP/AP [‡]	RS/AP	A/RSP	A/RS	Non-aspirin [‡]	Aspirin	Non-RS [‡]	RS
At baseline § P-value	6.9 (31) 0.12	4.3 (20) 0.12	4.0 (25) 0.07	4.6 (19) 0.41	5.8 (51)	4.3 (44) 0.31	5.6 (56)	4.4 (39) 0.55
Final largest polyp size for all patients // P-value	6.5 (31)	4.0 (20)	3.4 (25)	4.4 (19)	5.5 (51)	3.8 (44)	5.1 (56)	4.2 (39)
P-value		0.03	0.006	0.07		0.05		0.27
P-value adjusted for baseline		0.10	0.03	0.11		0.09		0.35
Final largest polyp size for patients treated for more than one year P-value P-value adjusted for baseline	6.5 (17)	4.6 (7) 0.26 0.42	2.9 (8) 0.03 0.09	3.1 (9) 0.02 0.03	6.0 (24)	3.0 (17) 0.01 0.02	5.4 (25)	3.8 (16) 0.17 0.19

Abbreviations: N, number; RSP, RS placebo; AP, A placebo.

* Raw means presented, log transformed measures used in tests.

[†]The p-values are from linear regression for the following comparisons: RS/P versus P/P, A/P versus P/P an A/RS versus P/P.

[‡]Reference group in the linear regression models.

§ 23/133 Patients did not have polyps measured at baseline, and 15/133 patients did not have polyps measured throughout the study. Numbers are based on patients who also have a result post-baseline.

//Numbers are based on patients who also have a baseline result.